https://www.forex-news.com/
Forex-News has been the world leading economy news website since 2005. It has been a joyful path full of changing variables in this changing world. During the last three years we have also covered some of the most important news regarding Bitcoin and other cryptocurrencies. Wherever the news are, we are there.
, Biontech – conclusion of the day | message, Forex-News, Forex-News
Bitcoin
$42,201.54
-1616.22
Ethereum
$2,894.01
-209.03
Litecoin
$148.67
-11.2
DigitalCash
$163.75
-19.66
Monero
$232.84
-13.21
Nxt
$0.01
-0
Ethereum Classic
$46.66
-3.83
Dogecoin
$0.21
-0.01

Biontech – conclusion of the day | message

15
, Biontech – conclusion of the day | message, Forex-News, Forex-News

[ad_1]

, Biontech – conclusion of the day | message, Forex-News, Forex-News

, Biontech – conclusion of the day | message, Forex-News, Forex-NewsDear stock exchange traders, Biontech is a prime example of volatility and shows how quickly you can and must become active on the stock market. Act. We find – a (our) stock exchange service – to be found here – must have three attributes: immediate accessibility for readers, speed in implementation and seriously good recommendations. But we also want to exemplify this for once. Our thought on Wednesday afternoon – Biontech was almost 20% in the red – time for a “counter trade”. Decided at 3:30 p.m., with the reader including product 10 minutes later. Just look how it looks with us. Because – a few hours later we were able to report a delay and our subscribers had a nice profit.

Mail 3.40 p.m .:

Dear subscribers, In the video, Daniel discusses our short-term trades on the DAX and some basic aspects of inline warrants and the latest promotions and depots and hotlist. Real music is on Thursday Biontech and CureVac. After we took our bear off the hotlist on Biontech in Plus, we are now giving you the counter-trade and taking the bull KE127A with lever 2 on the Hotlist. Actually, such completely flipped trades are rather uncommon for us, but the movement was extreme within hours. Biontech remains an exciting stock and there is still a lot of imagination in this area of ​​vaccination, also with regard to annual vaccinations. This factor cannot be ignored and it could make vaccine stocks profitable for decades.

mail 8:05 p.m .:

Dear subscribers,

The trading idea on Biontech worked perfectly. Collects the winnings in the WKN KE127A. We’ll take the ticket off the hotlist with a profit of around 25 percent. We wish you a nice evening and will be in touch tomorrow with a detailed video that also deals with risk management in the depot.

Thus, dear people actively trading on the stock exchange, Feingold Research has proven to be Stock exchange service written on the flags to “take you by the hand” with your wealth accumulation, with your actions in the financial market. What does that mean? Most stock market magazines and stock exchange services have recommendations based on the motto “eat or die”. We explain every trade, purchase or sale. We take those by the hand who want to get started with ETFs or pure shares or low-leveraged shares in the branded portfolio. We have the big stock exchange service for all comprehensive services across all asset classes, from gold to Bitcoin to currencies and stocks.

Those who approach the stock market and / or want to spend less time on the stock market are in very good hands with our brand strength and wealth accumulation module. The focus there is on our brand portfolio with high-growth stocks. We also present interesting ETFs and discuss current opportunities and risks in the markets.

Speculative investors are best catered for in the turbo service and warrant portfolio. Above all, we have answers to all of your questions via classic email contact. Quickly and personally. Where do I buy shares, where do I open my securities account, how does leverage paper work, why do I buy paper a rather than paper b, how do I secure my assets, how do I invest without stress, what return can I expect, what mistakes can I avoid , I control my depot and so much more. New types of app or broker rely on complete personal responsibility and operate according to the motto “the main thing is cheap”.

We are not the main thing cheap, but the main thing is completely explanatory, holistic in our support and just what our subscribers appreciate and why 97.5% have been and stay with us since the start in 2018 – we TAKE YOUR HANDS -whether a speculative trader or a long-term, quiet investor. With a lot of background knowledge about the market, with audios for you, explanatory videos – everything you could hope for from a reputable stock exchange service. Do you want impressions of who we are? Well – Daniel can be seen weekly on n-tv, for example to be seen here at Easter 2021 or in the low of 2020 with an egg or a rubber ball – watch here. Benjamin Feingold has 30 years of stock market experience, author of trading in derivatives. Nicolas Saurenz has 15 years of experience and covers all new developments in brokers and on the US market. Franz-Georg Wenner is our expert for technical analysis – proven since 2008 as a technical analyst at Börse Online / FTD.

, Biontech – conclusion of the day | message, Forex-News, Forex-NewsOur services in detail with the respective time expenditure and what awaits you – you will find that here on a specially set up landing page.

We wish you every success in the stock market and have fun with our references and we look forward to welcoming you. By the way, you don’t have to take out an annual subscription right away, we also offer everything that can be canceled on a monthly basis. We take by the hand and do not tie anyone. Quality matters. Your TEAM Feingold Research

, Biontech – conclusion of the day | message, Forex-News, Forex-News

Continue to the full article at “Feingold Research”

[ad_2]

, Biontech – conclusion of the day | message, Forex-News, Forex-News

Get real time updates directly on you device, subscribe now.

, Biontech – conclusion of the day | message, Forex-News, Forex-News

Leave A Reply

Your email address will not be published.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More